Abstract

Anemia is a frequent complication of kidney disease. When severe, it causes symptoms that can be debilitating. The course of anemia tends to track the decline in kidney function, with prevalence increasing in more advanced disease. Although the most common cause is relative erythropoietin deficiency, other factors such as reduced iron availability contribute to the pathobiology. In this review, we use cases to explore the surprising complexity of decision-making in management of renal anemia.

REFERENCES

1.
Bright
R
.
Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine
.
Guys Hosp Rep
.
1836
;
1
:
340
-
350
.
2.
Babitt
JL
,
Lin
HY
.
Mechanisms of anemia in CKD
.
J Am Soc Nephrol
.
2012
;
23
(
10
):
1631
-
1634
.
3.
Levey
AS
,
Coresh
J
,
Tighiouart
H
,
Greene
T
,
Inker
LA
.
Measured and estimated glomerular filtration rate: current status and future directions
.
Nat Rev Nephrol
.
2020
;
16
(
1
):
51
-
64
.
4.
Levin
A
,
Stevens
PE
,
Bilous
RW
, et al;
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
.
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease
.
Kidney Int Suppl
.
2013
;
3
(
1
):
1
-
150
.
5.
McClellan
W
,
Aronoff
SL
,
Bolton
WK
, et al
.
The prevalence of anemia in patients with chronic kidney disease
.
Curr Med Res Opin
.
2004
;
20
(
9
):
1501
-
1510
.
6.
Arbor Research Collaborative for Health
.
DOPPS Practice Monitor. National sample: weekly IV epoetin dose received (30 day average), categories
. https://www.dopps.org/DPM/DPMSlideBrowser.aspx?type=Topic&id=1&g=sum_EPOIV30DAY_c_overall.
Accessed 6 September 2019
.
7.
Mercadal
L
,
Metzger
M
,
Casadevall
N
, et al;
NephroTest Study Group
.
Timing and determinants of erythropoietin deficiency in chronic kidney disease
.
Clin J Am Soc Nephrol
.
2012
;
7
(
1
):
35
-
42
.
8.
Malyszko
J
,
Mysliwiec
M
.
Hepcidin in anemia and inflammation in chronic kidney disease
.
Kidney Blood Press Res
.
2007
;
30
(
1
):
15
-
30
.
9.
Ueda
N
,
Takasawa
K
.
Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease
.
Nutrients
.
2018
;
10
(
9
):
E1173
.
10.
Ganz
T
.
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
.
Blood
.
2003
;
102
(
3
):
783
-
788
.
11.
Ratcliffe
LE
,
Thomas
W
,
Glen
J
, et al
.
Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rationale
.
Am J Kidney Dis
.
2016
;
67
(
4
):
548
-
558
.
12.
Troutt
JS
,
Butterfield
AM
,
Konrad
RJ
.
Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates
.
J Clin Lab Anal
.
2013
;
27
(
6
):
504
-
510
.
13.
Anderson
GJ
,
Frazer
DM
.
Current understanding of iron homeostasis
.
Am J Clin Nutr
.
2017
;
106
(
suppl 6
):
1559S
-
1566S
.
14.
Stancu
S
,
Stanciu
A
,
Zugravu
A
, et al
.
Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD
.
Am J Kidney Dis
.
2010
;
55
(
4
):
639
-
647
.
15.
Fishbane
S
,
Kowalski
EA
,
Imbriano
LJ
,
Maesaka
JK
.
The evaluation of iron status in hemodialysis patients
.
J Am Soc Nephrol
.
1996
;
7
(
12
):
2654
-
2657
.
16.
Macdougall
IC
,
Bock
AH
,
Carrera
F
, et al;
FIND-CKD Study Investigators
.
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
.
Nephrol Dial Transplant
.
2014
;
29
(
11
):
2075
-
2084
.
17.
Agarwal
R
,
Kusek
JW
,
Pappas
MK
.
A randomized trial of intravenous and oral iron in chronic kidney disease
.
Kidney Int
.
2015
;
88
(
4
):
905
-
914
.
18.
Macdougall
IC
,
Tucker
B
,
Thompson
J
,
Tomson
CR
,
Baker
LR
,
Raine
AE
.
A randomized controlled study of iron supplementation in patients treated with erythropoietin
.
Kidney Int
.
1996
;
50
(
5
):
1694
-
1699
.
19.
Fishbane
S
,
Frei
GL
,
Maesaka
J
.
Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation
.
Am J Kidney Dis
.
1995
;
26
(
1
):
41
-
46
.
20.
Finkelstein
FO
,
Story
K
,
Firanek
C
, et al
.
Health-related quality of life and hemoglobin levels in chronic kidney disease patients
.
Clin J Am Soc Nephrol
.
2009
;
4
(
1
):
33
-
38
.
21.
Finkelstein
FO
,
Finkelstein
SH
.
The impact of anemia treatment on health-related quality of life in patients with chronic kidney disease in the contemporary era
.
Adv Chronic Kidney Dis
.
2019
;
26
(
4
):
250
-
252
.
22.
Pfeffer
MA
,
Burdmann
EA
,
Chen
C-Y
, et al;
TREAT Investigators
.
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
.
N Engl J Med
.
2009
;
361
(
21
):
2019
-
2032
.
23.
Collister
D
,
Komenda
P
,
Hiebert
B
, et al
.
The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis
.
Ann Intern Med
.
2016
;
164
(
7
):
472
-
478
.
24.
Collins
AJ
,
Ma
JZ
,
Ebben
J
.
Impact of hematocrit on morbidity and mortality
.
Semin Nephrol
.
2000
;
20
(
4
):
345
-
349
.
25.
Singh
AK
,
Szczech
L
,
Tang
KL
, et al;
CHOIR Investigators
.
Correction of anemia with epoetin alfa in chronic kidney disease
.
N Engl J Med
.
2006
;
355
(
20
):
2085
-
2098
.
26.
Besarab
A
,
Bolton
WK
,
Browne
JK
, et al
.
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
.
N Engl J Med
.
1998
;
339
(
9
):
584
-
590
.
27.
Coyne
DW
.
The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial
.
Kidney Int
.
2012
;
82
(
2
):
235
-
241
.
28.
Kidney Disease: Improving Global Outcomes (KDIGO)
.
KDIGO clinical practice guideline for anemia in chronic kidney disease
.
Kidney Int Suppl
.
2012
;
2
(
4
):
282
-
335
.
29.
Mehdi
U
,
Toto
RD
.
Anemia, diabetes, and chronic kidney disease
.
Diabetes Care
.
2009
;
32
(
7
):
1320
-
1326
.
30.
Mazer
CD
,
Hare
GMT
,
Connelly
PW
, et al
.
Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease
.
Circulation
.
2020
;
141
(
8
):
704
-
707
.
31.
US Food and Drug Administration
.
Aranesp (darbepoetin alfa): for injection
. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103951s5197lbl.pdf.
Accessed 19 November 2019
.
32.
Leffell
MS
,
Kim
D
,
Vega
RM
, et al
.
Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation
.
Transplantation
.
2014
;
97
(
5
):
525
-
533
.
33.
Drüeke
TB
,
Locatelli
F
,
Clyne
N
, et al;
CREATE Investigators
.
Normalization of hemoglobin level in patients with chronic kidney disease and anemia
.
N Engl J Med
.
2006
;
355
(
20
):
2071
-
2084
.
34.
Szczech
LA
,
Barnhart
HX
,
Inrig
JK
, et al
.
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes
.
Kidney Int
.
2008
;
74
(
6
):
791
-
798
.
35.
Arbor Research Collaborative for Health
.
DOPPS Practice Monitor. National sample: hemoglobin (most recent), categories
. https://www.dopps.org/dpm/DPMSlideBrowser.aspx?type=Topic&id=1.
Accessed 26 February 2020
.
36.
Husain-Syed
F
,
McCullough
PA
,
Birk
HW
, et al
.
Cardio-pulmonary-renal interactions: a multidisciplinary approach
.
J Am Coll Cardiol
.
2015
;
65
(
22
):
2433
-
2448
.
37.
Savarese
G
,
Jonsson
Å
,
Hallberg
AC
,
Dahlström
U
,
Edner
M
,
Lund
LH
.
Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum
.
Int J Cardiol
.
2020
;
298
:
59
-
65
.
38.
Anker
SD
,
Comin Colet
J
,
Filippatos
G
, et al;
FAIR-HF Trial Investigators
.
Ferric carboxymaltose in patients with heart failure and iron deficiency
.
N Engl J Med
.
2009
;
361
(
25
):
2436
-
2448
.
39.
Nakano
H
,
Nagai
T
,
Sundaram
V
, et al;
NaDEF investigators
.
Impact of iron deficiency on long-term clinical outcomes of hospitalized patients with heart failure
.
Int J Cardiol
.
2018
;
261
:
114
-
118
.
40.
Ebner
N
,
Jankowska
EA
,
Ponikowski
P
, et al
.
The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure
.
Int J Cardiol
.
2016
;
205
:
6
-
12
.
41.
Kapoor
M
,
Schleinitz
MD
,
Gemignani
A
,
Wu
WC
.
Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: a meta-analysis
.
Cardiovasc Hematol Disord Drug Targets
.
2013
;
13
(
1
):
35
-
44
.
42.
Klip
IT
,
Comin-Colet
J
,
Voors
AA
, et al
.
Iron deficiency in chronic heart failure: an international pooled analysis
.
Am Heart J
.
2013
;
165
(
4
):
575
-
582.e3
.
43.
Melenovsky
V
,
Petrak
J
,
Mracek
T
, et al
.
Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis
.
Eur J Heart Fail
.
2017
;
19
(
4
):
522
-
530
.
44.
Anker
SD
,
Kirwan
BA
,
van Veldhuisen
DJ
, et al
.
Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis
.
Eur J Heart Fail
.
2018
;
20
(
1
):
125
-
133
.
45.
Swedberg
K
,
Young
JB
,
Anand
IS
, et al;
RED-HF Committees
;
RED-HF Investigators
.
Treatment of anemia with darbepoetin alfa in systolic heart failure
.
N Engl J Med
.
2013
;
368
(
13
):
1210
-
1219
.
46.
van der Meer
P
,
Grote Beverborg
N
,
Pfeffer
MA
, et al
.
Hyporesponsiveness to darbepoetin alfa in patients with heart failure and anemia in the RED-HF study (reduction of events by darbepoetin alfa in heart failure): clinical and prognostic associations
.
Circ Heart Fail
.
2018
;
11
(
2
):
e004431
.
47.
Butler
AM
,
Olshan
AF
,
Kshirsagar
AV
, et al
.
Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009
.
Am J Kidney Dis
.
2015
;
65
(
5
):
763
-
772
.
48.
Aapro
M
,
Jelkmann
W
,
Constantinescu
SN
,
Leyland-Jones
B
.
Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
.
Br J Cancer
.
2012
;
106
(
7
):
1249
-
1258
.
49.
Miskulin
DC
,
Tangri
N
,
Bandeen-Roche
K
, et al;
Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Network Patient Outcomes in End Stage Renal Disease Study Investigators
.
Intravenous iron exposure and mortality in patients on hemodialysis
.
Clin J Am Soc Nephrol
.
2014
;
9
(
11
):
1930
-
1939
.
50.
Macdougall
IC
,
White
C
,
Anker
SD
, et al;
PIVOTAL Investigators and Committees
.
Intravenous iron in patients undergoing maintenance hemodialysis
.
N Engl J Med
.
2019
;
380
(
5
):
447
-
458
.
51.
Coyne
DW
,
Brennan
DC
.
Seeking safe and efficacious anemia management
.
Semin Dial
.
2009
;
22
(
5
):
590
-
591
.
You do not currently have access to this content.

Sign in via your Institution

Sign In